Oncology

Discovery
IND-enabling
Phase 1
Phase 2
Phase 3
Trifecta MEK

Title

8%
KRAS4B

Title

8%
RAS induction

Title

8%
Covalent-MEK

Title

8%
PI3K-alpha

Title

8%

Neuroscience

IMM-ALL-01

Title

8%
IMM-ALL-03

Title

8%

More than half of all tumors rely on inappropriate activation of the RAS/RAF/MEK pathway, yet existing drugs targeting this pathway are limited by toxicity or are narrowly focused on subpopulations with specific mutations. Immuneering’s novel drug candidates spare healthy normal cells by modulating cell signaling dynamics to selectively impact tumor cells.

Oncology – Select Therapies

Dual-MEK inh

Our MEK product candidate, IMM-1-104, aims to achieve pan-KRAS/NRAS activity that selectively impacts cancer cells to a greater extent than healthy cells. It is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR to modulate the signaling dynamics of the MAPK pathway by driving deep cyclic inhibition that deprives tumor cells of the sustained proliferative signaling required for rapid growth, while providing a cadenced, moderate level of signaling designed to spare healthy cells. IMM-1-104 is being developed to treat advanced solid tumors in patients harboring RAS mutations. 

MEK-io

Our MEK-immuno-oncology MEK-io program is focused on developing innovative allosteric MEK inhibitors to be administered in combination with select immune modulators (e.g., checkpoint inhibitors) for the treatment of “cold” solid tumors, which are immunologically inaccessible. Our investigational MEK-io, IMM-6-415, is designed with unique pharmacokinetic and pharmacodynamic profiles that may enhance cycle inhibition time of MEK and ERK to optimize the patient’s immune response and promote maximal antitumor responses when administered in combination with select immune modulators.

Alzheimer’s

For most Alzheimer’s patients, there is no clear trajectory of disease progression or worsening symptoms. In fact, even clinical presentation can be widely different from individual to individual, suggesting that Alzheimer’s is less of a disease and more of a syndrome. Integrating brain gene expression and Alzheimer’s marker data offers the potential to stratify patients into subgroups with unique biology and identify targets specific to these subgroups. We aim to be leaders in delivering effective precision medicines to patients suffering with Alzheimer’s disease globally.